455 related articles for article (PubMed ID: 25283841)
21. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
Geenen JJJ; Schellens JHM
Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
23. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
[TBL] [Abstract][Full Text] [Related]
24. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
[TBL] [Abstract][Full Text] [Related]
25. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
26. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
27. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q
Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486
[TBL] [Abstract][Full Text] [Related]
28. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
29. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited.
Potapova TA; Sivakumar S; Flynn JN; Li R; Gorbsky GJ
Mol Biol Cell; 2011 Apr; 22(8):1191-206. PubMed ID: 21325631
[TBL] [Abstract][Full Text] [Related]
30. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
[TBL] [Abstract][Full Text] [Related]
31. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
32. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
[TBL] [Abstract][Full Text] [Related]
33. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
34. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
36. A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.
Massacci G; Venafra V; Latini S; Bica V; Pugliese GM; Graziosi S; Klingelhuber F; Krahmer N; Fischer T; Mougiakakos D; Boettcher M; Perfetto L; Sacco F
Leukemia; 2023 Feb; 37(2):288-297. PubMed ID: 36509894
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
Mak JP; Man WY; Ma HT; Poon RY
Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
[TBL] [Abstract][Full Text] [Related]
38. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
40. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
